Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice

Cardiovascular Diabetology
Enrico LongatoGian Paolo Fadini

Abstract

Cardiovascular outcome trials in high-risk patients showed that some GLP-1 receptor agonists (GLP-1RA), but not dipeptidyl-peptidase-4 inhibitors (DPP-4i), can prevent cardiovascular events in type 2 diabetes (T2D). Since no trial has directly compared these two classes of drugs, we performed a comparative outcome analysis using real-world data. From a database of ~ 5 million people from North-East Italy, we retrospectively identified initiators of GLP-1RA or DPP-4i from 2011 to 2018. We obtained two balanced cohorts by 1:1 propensity score matching. The primary outcome was the 3-point major adverse cardiovascular events (3P-MACE; a composite of death, myocardial infarction, or stroke). 3P-MACE components and hospitalization for heart failure were secondary outcomes. From 330,193 individuals with T2D, we extracted two matched cohorts of 2807 GLP-1RA and 2807 DPP-4i initiators, followed for a median of 18 months. On average, patients were 63 years old, 60% male; 15% had pre-existing cardiovascular disease. The rate of 3P-MACE was lower in patients treated with GLP-1RA compared to DPP4i (23.5 vs. 34.9 events per 1000 person-years; HR: 0.67; 95% C.I. 0.53-0.86; p = 0.002). Rates of myocardial infarction (HR 0.67; 95% C.I. 0.50-0.9...Continue Reading

References

Jun 1, 1992·Journal of Clinical Epidemiology·R A DeyoM A Ciol
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
May 28, 2010·Diabetes Research and Clinical Practice·Wenying YangPhilip D Home
Mar 4, 2011·The New England Journal of Medicine·Sreenivasa Rao Kondapally SeshasaiUNKNOWN Emerging Risk Factors Collaboration
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Aug 16, 2016·Cardiovascular Diabetology·Angelo AvogaroStefano Del Prato
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Sep 15, 2017·The New England Journal of Medicine·Rury R HolmanUNKNOWN EXSCEL Study Group
Jan 25, 2018·Diabetes, Obesity & Metabolism·Sudesna ChatterjeeKamlesh Khunti
Dec 12, 2018·The Lancet. Diabetes & Endocrinology·Henrik SvanströmBjörn Pasternak
Dec 14, 2018·Cardiovascular Diabetology·Andrei C SpositoJosé Francisco Kerr Saraiva
Dec 24, 2018·The New England Journal of Medicine·UNKNOWN GBD 2016 Lifetime Risk of Stroke CollaboratorsGregory A Roth
Apr 9, 2019·Circulation·Elisabetta PatornoSebastian Schneeweiss
Aug 30, 2019·Cardiovascular Diabetology·Yue FeiBernard Man Yung Cheung
Sep 10, 2019·European Heart Journal·Francesco CosentinoUNKNOWN ESC Scientific Document Group
Apr 18, 2020·The Journal of Clinical Endocrinology and Metabolism·Mario Luca MorieriGian Paolo Fadini

❮ Previous
Next ❯

Citations

Nov 19, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Mario Luca MorieriGian Paolo Fadini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.